Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
National Institutes of Health
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Oct 23, 2025
- Amount
- $300,000
- Closes
- Nov 10, 2026
Similar opportunities open now
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Nov 10, 2026Up to $150K
- NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Nov 2029
- Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Nov 2028
- NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Apr 2027
Classification and identifiers
- Solicitation number
- RFA-CA-27-002
- Assistance listing (CFDA)
- 93.394
Amount
$300,000
Who can apply
State government agencies, Public colleges and universities, and Nonprofits can all apply here. Check the eligibility details below to see if your organization fits.
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
About this opportunity
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites grant applications proposing exploratory research projects focused on further development and technical validation of emerging technologies offering novel capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens used for basic, clinical, or epidemiological cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous technical validation to encourage adoption by the research community. Well-suited applications must propose the development of technologi...